Cargando…
Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score
IgA nephropathy (IgAN) is a common cause of end-stage renal disease (ESRD) in Asia. In this study, based on a large cohort of Chinese patients with IgAN, we aim to identify independent predictive factors associated with disease progression to ESRD. We collected retrospective clinical data and renal...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375310/ https://www.ncbi.nlm.nih.gov/pubmed/22719981 http://dx.doi.org/10.1371/journal.pone.0038904 |
_version_ | 1782235750782205952 |
---|---|
author | Xie, Jingyuan Kiryluk, Krzysztof Wang, Weiming Wang, Zhaohui Guo, Shanmai Shen, Pingyan Ren, Hong Pan, Xiaoxia Chen, Xiaonong Zhang, Wen Li, Xiao Shi, Hao Li, Yifu Gharavi, Ali G. Chen, Nan |
author_facet | Xie, Jingyuan Kiryluk, Krzysztof Wang, Weiming Wang, Zhaohui Guo, Shanmai Shen, Pingyan Ren, Hong Pan, Xiaoxia Chen, Xiaonong Zhang, Wen Li, Xiao Shi, Hao Li, Yifu Gharavi, Ali G. Chen, Nan |
author_sort | Xie, Jingyuan |
collection | PubMed |
description | IgA nephropathy (IgAN) is a common cause of end-stage renal disease (ESRD) in Asia. In this study, based on a large cohort of Chinese patients with IgAN, we aim to identify independent predictive factors associated with disease progression to ESRD. We collected retrospective clinical data and renal outcomes on 619 biopsy-diagnosed IgAN patients with a mean follow-up time of 41.3 months. In total, 67 individuals reached the study endpoint defined by occurrence of ESRD necessitating renal replacement therapy. In the fully adjusted Cox proportional hazards model, there were four baseline variables with a significant independent effect on the risk of ESRD. These included: eGFR [HR = 0.96(0.95–0.97)], serum albumin [HR = 0.47(0.32–0.68)], hemoglobin [HR = 0.79(0.72–0.88)], and SBP [HR = 1.02(1.00–1.03)]. Based on these observations, we developed a 4-variable equation of a clinical risk score for disease progression. Our risk score explained nearly 22% of the total variance in the primary outcome. Survival ROC curves revealed that the risk score provided improved prediction of ESRD at 24th, 60th and 120th month of follow-up compared to the three previously proposed risk scores. In summary, our data indicate that IgAN patients with higher systolic blood pressure, lower eGFR, hemoglobin, and albumin levels at baseline are at a greatest risk of progression to ESRD. The new progression risk score calculated based on these four baseline variables offers a simple clinical tool for risk stratification. |
format | Online Article Text |
id | pubmed-3375310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33753102012-06-20 Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score Xie, Jingyuan Kiryluk, Krzysztof Wang, Weiming Wang, Zhaohui Guo, Shanmai Shen, Pingyan Ren, Hong Pan, Xiaoxia Chen, Xiaonong Zhang, Wen Li, Xiao Shi, Hao Li, Yifu Gharavi, Ali G. Chen, Nan PLoS One Research Article IgA nephropathy (IgAN) is a common cause of end-stage renal disease (ESRD) in Asia. In this study, based on a large cohort of Chinese patients with IgAN, we aim to identify independent predictive factors associated with disease progression to ESRD. We collected retrospective clinical data and renal outcomes on 619 biopsy-diagnosed IgAN patients with a mean follow-up time of 41.3 months. In total, 67 individuals reached the study endpoint defined by occurrence of ESRD necessitating renal replacement therapy. In the fully adjusted Cox proportional hazards model, there were four baseline variables with a significant independent effect on the risk of ESRD. These included: eGFR [HR = 0.96(0.95–0.97)], serum albumin [HR = 0.47(0.32–0.68)], hemoglobin [HR = 0.79(0.72–0.88)], and SBP [HR = 1.02(1.00–1.03)]. Based on these observations, we developed a 4-variable equation of a clinical risk score for disease progression. Our risk score explained nearly 22% of the total variance in the primary outcome. Survival ROC curves revealed that the risk score provided improved prediction of ESRD at 24th, 60th and 120th month of follow-up compared to the three previously proposed risk scores. In summary, our data indicate that IgAN patients with higher systolic blood pressure, lower eGFR, hemoglobin, and albumin levels at baseline are at a greatest risk of progression to ESRD. The new progression risk score calculated based on these four baseline variables offers a simple clinical tool for risk stratification. Public Library of Science 2012-06-14 /pmc/articles/PMC3375310/ /pubmed/22719981 http://dx.doi.org/10.1371/journal.pone.0038904 Text en Xie et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Xie, Jingyuan Kiryluk, Krzysztof Wang, Weiming Wang, Zhaohui Guo, Shanmai Shen, Pingyan Ren, Hong Pan, Xiaoxia Chen, Xiaonong Zhang, Wen Li, Xiao Shi, Hao Li, Yifu Gharavi, Ali G. Chen, Nan Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score |
title | Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score |
title_full | Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score |
title_fullStr | Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score |
title_full_unstemmed | Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score |
title_short | Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score |
title_sort | predicting progression of iga nephropathy: new clinical progression risk score |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375310/ https://www.ncbi.nlm.nih.gov/pubmed/22719981 http://dx.doi.org/10.1371/journal.pone.0038904 |
work_keys_str_mv | AT xiejingyuan predictingprogressionofiganephropathynewclinicalprogressionriskscore AT kirylukkrzysztof predictingprogressionofiganephropathynewclinicalprogressionriskscore AT wangweiming predictingprogressionofiganephropathynewclinicalprogressionriskscore AT wangzhaohui predictingprogressionofiganephropathynewclinicalprogressionriskscore AT guoshanmai predictingprogressionofiganephropathynewclinicalprogressionriskscore AT shenpingyan predictingprogressionofiganephropathynewclinicalprogressionriskscore AT renhong predictingprogressionofiganephropathynewclinicalprogressionriskscore AT panxiaoxia predictingprogressionofiganephropathynewclinicalprogressionriskscore AT chenxiaonong predictingprogressionofiganephropathynewclinicalprogressionriskscore AT zhangwen predictingprogressionofiganephropathynewclinicalprogressionriskscore AT lixiao predictingprogressionofiganephropathynewclinicalprogressionriskscore AT shihao predictingprogressionofiganephropathynewclinicalprogressionriskscore AT liyifu predictingprogressionofiganephropathynewclinicalprogressionriskscore AT gharavialig predictingprogressionofiganephropathynewclinicalprogressionriskscore AT chennan predictingprogressionofiganephropathynewclinicalprogressionriskscore |